Dose and duration of hormone use: Understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004

Journal of Epidemiology and Community Health

Volumn 59, Issue 12, 2005, Pages 1078-1079

  McPherson, Klim ^a,b   Mant, Rebecca ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE; PROGESTERONE;

CANCER;

ARTICLE; BREAST CANCER; CANCER RISK; DRUG EFFECT; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MENOPAUSE; RELIABILITY; SIDE EFFECT; UNITED KINGDOM;

BREAST NEOPLASMS; ESTROGENS; FEMALE; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; PROGESTERONE;

EID: 28444478391     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2005.035147     Document Type: Article

References (20)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59.
2. ACOG committee opinion. Risk of breast cancer with estrogen+progetin replacement therapy. Int J Obs Gynecol 2002;76:333-5.
3. Stahlberg C, Pedersen AT, Lynge E, et al. Hormone replacement therapy and the risk of breast cancer: the role of progestins. Acta Obstet Gynaecol 2003;82:335-44.
4. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-27.
5. The Women's Health Initiative Study Group. Effects of conjugated equine estrogen in post menopausal women with hysterectomy: the WHI randomised controlled trial. JAMA 2004;291:1701-12.
6. Townsend J. Hormone replacement therapy: assessment of present use, costs, and trends. Br J Gen Pract 1998;48:955-8.
7. Eggar M, Davey Smith G, Altman D. Systematic reviews in health care. London: BMJ Books, 2001.
8. Hunt K, Vessey M, McPherson K, et al. Long term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-35.
9. Ewertz M, et al. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832-8.
10. Bergkvist K, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
11. Harris RE, Namboodiri KK, Wynder EL. Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992;84:1575-82.
12. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788-95.
13. Stanford JL, Weiss NS, Voigt LF, et al. Combines estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
14. Magnusson C, Baron JA, Correia N, et al. Breast cancer risk following long term oestrogen and oestrogen-progestin replacement therapy. Int J Cancer 1999;81:339-44.
15. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer. JAMA 2000;283:485-91.
16. Ross RK, Paganin-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk. J Natl Cancer Inst 2000;92:328-32.
17. Chlebowski R, Hendrix S, Langer R, et al. Influence of estrogen plus progestins on breast cancer and mammography in healthy postmenopausal women. JAMA 2003;289:3243-53.
18. Li C, Malone K, Porter P, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
19. Salpeter SJ, Walsh JME, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women. J Gen Intern Med 2004;19:791-804.
20. McPherson K, Hemminki E. Synthesising licensing data to assess drug safety. BMJ 2004;328:518-20.